White matter microstructure deteriorates across cognitive stages in Parkinson disease

Neurology

Volumn 80, Issue 20, 2013, Pages 1841-1849

  Melzer, Tracy R ^a,b   Watts, Richard ^a,c   Macaskill, Michael R ^a,b   Pitcher, Toni L ^a,b   Livingston, Leslie ^a,b   Keenan, Ross J ^d   Dalrymple Alford, John C ^a,b,e   Anderson, Tim J ^a,b,f  

^a NEW ZEALAND BRAIN RESEARCH INSTITUTE   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF VERMONT   (United States)

^d Christchurch Radiology Group   (New Zealand)

^e UNIVERSITY OF CANTERBURY   (New Zealand)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATTENTION; CONTROLLED STUDY; CORPUS CALLOSUM; DEMENTIA; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; ECHO PLANAR IMAGING; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PRIORITY JOURNAL; WHITE MATTER;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; PARKINSON DISEASE;

EID: 84879078050     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182929f62     Document Type: Article

References (40)

1. Braak H, Tredici KD, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
2. Aarsland D. Epidemiology of dementia associated with Parkinson's disease. In: Emre M, editor. Cognitive Impairment and Dementia in Parkinson's Disease. New York: Oxford University Press; 2010:5-14.
3. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011;26:629-636.
4. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
5. Martinez-Horta S, Kulisevsky J. Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? J Neural Transm 2011;118:1185-1190.
6. Rektorova I. Mild cognitive impairment exists in Parkinson's disease. J Neural Transm 2011;118:1179-1183.
7. Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:183-194.
8. Weintraub D, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011;68:1562-1568.
9. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003;4:469-480.
10. Karagulle Kendi AT, Lehericy S, Luciana M, et al. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008;29:501-505.
11. Wiltshire K, Concha L, Gee M, et al. Corpus callosum and cingulum tractography in Parkinson's disease. Can J Neurol Sci 2010;37:595-600.
12. Hattori T, Orimo S, Aoki S, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012;33:727-739.
13. Lee JE, Park HJ, Park B, et al. A comparative analysis of cognitive profiles and white-matter alterations using voxelbased diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010;81:320-326.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
15. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
16. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
17. Emre M, Aarsland D, Brown RG, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
18. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
19. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tractbased spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
20. Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012;59:3774-3783.
21. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83-98.
22. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol 2011;7:229-236.
23. Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:371-378.
24. Meyer JS, Huang J, Chowdhury MH. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci 2007;257:97-104.
25. Dalaker TO, Zivadinov R, Larsen JP, et al. Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 2010;25:629-633.
26. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010;25:687-688.
27. Matsui H, Nishinaka K, Oda M, et al. Wisconsin Card Sorting Test in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007;116:108-112.
28. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1383-1386.
29. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 2012;27:90-97.
30. Ibarretxe-Bilbao N, Junque C, Marti MJ, et al. Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: a voxel-based diffusion tensor imaging study. Mov Disord 2010;25:1888-1894.
31. Matsui H, Nishinaka K, Oda M, et al. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007;116:177-181.
32. Rae CL, Correia MM, Altena E, et al. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 2012;62:1675-1684.
33. Raichle ME. The restless brain. Brain Connect 2011;1:3-12.
34. Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA 2006;103:13848-13853.
35. Habib J, Auer DP, Morgan PS. A quantitative analysis of the benefits of cardiac gating in practical diffusion tensor imaging of the brain. Magn Reson Med 2010;63:1098-1103.
36. Degirmenci B, Yaman M, Haktanir A, et al. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease. Neurosci Lett 2007;416:294-298.
37. Beaulieu C. The basis of anisotropic water diffusion in the nervous system: a technical review. NMR Biomed 2002;15:435-455.
38. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000;247:II3-II10.
39. Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:827-828.
40. Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:829-830.